Review Article
Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
Table 2
Baseline characteristics of patients in included studies.
| | Chevalier et al. | Choi et al. | Kim et al. | Park et al. | Leon et al. |
| | Number studied | | | | | | | PES | 197 | 153 | 105 | 884 | 775 | | ZES | 199 | 86 | 47 | 883 | 773 | | Age | | | | | | | PES | 63 +/− 11 | 61.54 +/− 12.22 | 63 +/− 9 | 62.0 +/− 9.6 | 63.6 +/− 11.0 | | Zes | 63 +/− 10 | 60.24 +/− 11.76 | 59 +/− 12 | 61.7 +/− 9.3 | 63.5 +/− 11.1 | | Gender (male) | | | | | | | PES | 77% | 100 (65.4%) | 76 (72.4%) | 582 (65.8%) | 531 (68.5%) | | ZES | 75% | 69 (80.2%) | 37 (78.7%) | 586 (66.4%) | 517 (66.9%) | | Vessel location (LAD) | | | | | | | PES | 40% | 72 (47.1%) | 45 (42.9%) | 611 (50.7%) | 321 (41.5%) | | ZES | 48% | 45 (52.3%) | 30 (63.8%) | 622 (52.3%) | 326 (42.2%) | | Vessel location (LCx) | | | | | | | PES | 19% | 29 (19.0%) | 15 (14.2%) | 253 (21.0) | 202 (26.1%) | | ZES | 24% | 10 (11.6%) | 2 (4.3%) | 252 (21.2%) | 208 (26.9%) | | Vessel location (RCA) | | | | | | | PES | 41% | 52 (34.0%) | 45 (42.9) | 340 (28.2%) | 251 (32.4%) | | ZES | 28% | 31 (36.0%) | 15 (31.9%) | 316 (26.6) | 238 (30.8%) | | Diabetes mellitus | | | | | | | PES | 26% | 104 (68.0%) | 23 (21.9%) | 245 (27.7%) | 236 (30.5%) | | ZES | 22% | 64 (74.4%) | 12 (25.5%) | 268 (30.4%) | 241 (31.2%) | | Hypertension | | | | | | | PES | 67% | 86 (56.2%) | 50 (47.6%) | 540 (61.1%) | 640 (82.6%) | | ZES | 69% | 53 (61.6%) | 20 (43.5%) | 552 (62.5%) | 614 (79.4%) | | Hyperlipidemia | | | | | | | PES | 72% | 104 (68.2%) | 43 (41.3%) | 446 (50.5%) | 657 (84.8%) | | ZES | 78% | 57 (66.3%) | 18 (39.1%) | 466 (52.8%) | 629 (81.4) |
|
|
PES: paclitaxel-eluting stent; ZES: zotarolimus-eluting stent; LAD: left anterior descending coronary artery; LCx: left circumflex coronary artery; RCA: right coronary artery.
|
